24.09.2019 Views

AG&M annual report 2018

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

AG&M Science Impressions <strong>2018</strong><br />

Marc Besselink and Marin Strijker<br />

pancreatic resection are collected. The biobank started<br />

in 2015 and is incorporated in the Parelsnoer Institute,<br />

which is a nationwide network established by the Dutch<br />

Federation of University Medical Centers (NFU). The<br />

Parelsnoer Institute aims to facilitate central data and<br />

IT infrastructure in the UMC’s, striving for uniform data<br />

and biomaterial collection.<br />

All patients undergoing pancreatic resection are<br />

included. After providing informed consent, data and<br />

biomaterials are collected. In the preoperative setting<br />

DNA, plasma (10 mL tube) and serum (10 mL tube) are<br />

collected. Directly after resection, biopsies (2x tumor<br />

tissue, 1x normal pancreatic tissue, 1x normal spleen/<br />

duodenum) from the resected specimen are obtained;<br />

samples are fresh-frozen and stored at -80ºC. In the<br />

postoperative phase serum and plasma are collected at<br />

several moments during follow-up. This far, more than<br />

1300 patients have been included in 12 centers; all 8<br />

UMC’s, but also several teaching hospitals participate.<br />

Research proposals for the use of samples are<br />

evaluated by the DPCG scientific committee.<br />

ADAM12 as a stroma marker in<br />

pancreatic cancer<br />

Recently, the first analyses of samples from the Dutch<br />

Pancreas Biobank have been performed. This study,<br />

supervised by dr. Maarten Bijlsma, evaluates the<br />

serum marker A Disintegrin And Metalloprotease 12<br />

(ADAM12). Earlier research has shown that in patients<br />

with pancreatic cancer ADAM12 is upregulated<br />

specifically in the stroma of tumor tissue compared<br />

to normal pancreatic tissue. Moreover, in a cohort<br />

of 60 patients who underwent resection because of<br />

pancreatic cancer, high serum ADAM12 was associated<br />

with poor prognosis. In patients with metastatic disease<br />

treated with nab-paclitaxel and gemcitabine (n=184),<br />

low ADAM12 levels predicted response to treatment.<br />

The value of ADAM12 as a non-invasive biomarker<br />

in resected pancreatic cancer will be validated using<br />

samples from the Dutch Pancreas Biobank (n=164); the<br />

results are currently being analyzed.<br />

23

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!